The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Two Ipsen deals, together worth at least $670 million, reinforce that cancer and immune system drugs in late-stage testing remain some of the most attractive assets to biopharma buyers.

    Updated 4 hours ago
  • An aerial photo at night of Zhangjiang Hi-Tech Park, an industrial park in Shanghai that is home to multiple life sciences and tech companies.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    At BIO, tension over China biotech deal regulation looms

    Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.

    Updated July 1, 2026
  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Top FDA gene and cell therapy regulator to step down

    Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.

    FDA
  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences remaining in 2026

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch the rest of 2026.

    Updated June 25, 2026
  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    This year’s IPO class has already accounted for five of the six largest new biotech stock offerings since the start of 2022, according to BioPharma Dive data.

    Updated June 17, 2026
  • Light micrograph of crypt architectural distortion in inflammatory bowel disease.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Abivax shares surge as worries subside over immune drug’s cancer risk

    According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.

  • An Alkermes lab coat hangs in one of the company's offices.
    Image attribution tooltip
    Permission granted by Alkermes
    Image attribution tooltip
    Q&A

    Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda

    Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.

  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Viridian may have edge over Amgen in eye drug showdown, analysts argue

    The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Immune drugmakers carried the majority of venture financing in the second half of June, bringing in $608 million in total across five companies, according to BioPharma Dive data.

    Updated June 30, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

    The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

  • A bottle of pills lays on top of a sheet of $100 bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Theravance, after clinical setbacks, agrees to $929M buyout

    The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    To Wall Street, psychedelics biotechs are more teammates than rivals

    Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the psychedelic field and “bring it even further into the mainstream.”

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    AstraZeneca, Pfizer and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025 — surpassing all of their pharmaceutical peers over that timeframe.

    Updated June 1, 2026
  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    ‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs

    In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in offerings later this year — but only among companies fitting a certain criteria.

  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    Q&A // Emerging biotech

    How Kardigan spun deal leftovers into a $400M IPO

    CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.

  • Modern glass window office building facade with the logo of Bristol Myers Squibb.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Beeline ups its Series A round for immune drug work

    The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

    Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

  • Pill gavel
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    On second try, Acadia drug gets nod from European regulators

    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Ionis, with new FDA nod, hits a ‘commercial inflection point’

    Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar medicine in Tryngolza, which secured expanded approval Wednesday.

  • Wall street sign in New York City with New York Stock Exchange background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Remix to go public in reverse merger with once high-flying Passage Bio

    The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.

  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Antares gets $105M from Novartis for new cancer drugs

    Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Ollin refuels with $330M to back pivotal tests of Vabysmo challenger

    One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.

  • A micrograph image of influenza A virus.
    Image attribution tooltip
    NIAID. (2023). "Influenza A virus" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Emerging biotech

    Investors pour $115M into RQ Bio in search of a preventive flu drug

    The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor

    Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA struck a “build-to-buy” deal.

  • FDA magnifying glass
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    HHS, responding to China’s rise, moves to fast-track early drug research

    A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.